1. The bone ecosystem facilitates multiple myeloma relapse and the evolution of heterogeneous drug resistant disease.
- Author
-
Bishop, Ryan T., Miller, Anna K., Froid, Matthew, Nerlakanti, Niveditha, Li, Tao, Frieling, Jeremy S., Nasr, Mostafa M., Nyman, Karl J., Sudalagunta, Praneeth R., Canevarolo, Rafael R., Silva, Ariosto Siqueira, Shain, Kenneth H., Lynch, Conor C., and Basanta, David
- Subjects
MULTIPLE myeloma ,EMDR (Eye-movement desensitization & reprocessing) ,THERAPEUTICS ,TREATMENT effectiveness ,DISEASE relapse ,ECOSYSTEMS ,PLANT clones - Abstract
Multiple myeloma (MM) is an osteolytic malignancy that is incurable due to the emergence of treatment resistant disease. Defining how, when and where myeloma cell intrinsic and extrinsic bone microenvironmental mechanisms cause relapse is challenging with current biological approaches. Here, we report a biology-driven spatiotemporal hybrid agent-based model of the MM-bone microenvironment. Results indicate MM intrinsic mechanisms drive the evolution of treatment resistant disease but that the protective effects of bone microenvironment mediated drug resistance (EMDR) significantly enhances the probability and heterogeneity of resistant clones arising under treatment. Further, the model predicts that targeting of EMDR deepens therapy response by eliminating sensitive clones proximal to stroma and bone, a finding supported by in vivo studies. Altogether, our model allows for the study of MM clonal evolution over time in the bone microenvironment and will be beneficial for optimizing treatment efficacy so as to significantly delay disease relapse. Here, the authors develop a hybrid agent-based model to quantify the contributions of intrinsic cellular mechanisms and bone ecosystem factors to therapy resistance in multiple myeloma. They show that intrinsic mechanisms are essential for resistance, and that the bone microenvironment provides a protective niche that increases the likelihood. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF